![](https://ml.globenewswire.com/media/1644a38b-bed9-4a76-96fa-d57dd028e650/small/medicenna-jpg.jpg)
Medicenna Therapeutics to Participate in Two Healthcare Investor Conferences in February 2025
TORONTO and HOUSTON, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines for the treatment of cancer, and …